$33.0M
The Kent biotechnology spinout raised the capital from backers including XGEN Venture and the British Business Bank to push its lead treatment into clinical evaluation.
E
EpilepsyGTx
EpilepsyGTx develops targeted gene therapies for focal refractory epilepsy.
Kent, UK—Founded 2021
$33.0MTotal raised
A British biotechnology spinout developing targeted gene therapies for focal refractory epilepsy.
Categories
Founders
Nicolas Koebel
Chief Executive Officer
Nicolas serves as chief executive officer and founder of EpilepsyGTx. He previously held senior operational and general management roles at Orchard Therapeutics and GSK.
LinkedIn